Recovery, Anti-Aging & Optimization Therapies: Integrative & Alternative Medicine Approaches gaining attention.

At OMNI Wellspace, we are dedicated to providing  you with the tools and informational for a 
transformative journey toward optimal health through advanced
integrative therapies in aesthetic and integrative medicine. Our modalities are passionately designed to help enhance your overall aesthetic and wellness goals , metabolic health, and promote vibrant anti-aging from a cellular level that shows from the inside-out. We firmly ground our approach in the principles of evidence based care, integrative & 
alternative medicine, offering holistic and comprehensive modalities
for well-being from multiple perspectives. 

However we also believe It is also important to provide current evidence based information, safety data, & research available to our current & future readers and clients. 

Disclaimer

Important Regulatory Notices

  • Many peptides and wellness-modalities are not FDA-approved for the anti-aging, aesthetic, or wellness indications commonly promoted.

  • These treatments if ever discussed may be investigational, do not have FDA approval, or used off-label if available, for the purposes discussed; benefits are promising but not promoted, or offered to treat cure or prevent certain illness or disease; safety profiles may not be fully established.

  • The regulatory status of bulk substances (peptides) is evolving; the FDA has issued recent alerts for compounded GLP-1s and other peptide bulks.

Additional Information: References

GLP-1s (semaglutide)

  1. Lincoff AM, Wolski K, Nicholls SJ, et al. Semaglutide and cardiovascular outcomes in obesity. N Engl J Med. 2023;389(5):436-446. doi:10.1056/NEJMoa2307563. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

  3. Rubino DM, Greenway FL, Khalid U, et al. Two-year effects of semaglutide in adults with overweight/obesity (STEP 5). Nat Med. 2022;28:2083-2091. doi:10.1038/s41591-022-02026-4. https://www.nature.com/articles/s41591-022-02026-4

  4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844. doi:10.1056/NEJMoa1607141. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141

Sermorelin (GHRH 1-29)
8. Walker TB, Bemben MG. Sermorelin: physiology and clinical applications. Clin Interv Aging. 2010;5:235-243. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957188/

NAD⁺ / NR / NMN
9. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside elevates NAD⁺ in humans. Proc Natl Acad Sci USA. 2016;113(21):E1436-E1445. doi:10.1073/pnas.1601557113. https://www.pnas.org/doi/10.1073/pnas.1601557113
10. Martens CR, Denman BA, Mazzo-Mair JG, et al. Chronic nicotinamide riboside in healthy middle-aged/older adults: randomized, double-blind, placebo-controlled. Nat Commun. 2018;9:1286. doi:10.1038/s41467-018-03421-7. https://www.nature.com/articles/s41467-018-03421-7

Glutathione
11. Handog EB, Datuin MS, Singzon IA. Oral glutathione as a skin-lightening agent: randomized, double-blind, placebo-controlled. J Dermatol. 2014;41(3):213-218. doi:10.1111/1346-8138.12339. https://pubmed.ncbi.nlm.nih.gov/24572043/
12. Arjinpathana N, Asawanonda P. Glutathione for skin lightening: randomized, double-blind, placebo-controlled. J Dermatol Treat. 2012;23(2):97-102. doi:10.3109/09546634.2010.543714. https://pubmed.ncbi.nlm.nih.gov/21272078/
13. Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and oxidized glutathione lozenges improve skin properties. Clin Cosmet Investig Dermatol. 2017;10:29-35. doi:10.2147/CCID.S118156. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228693/

Methylene blue
14. Duong TT, Rowlands DS, et al. Methylene blue modulates functional connectivity in humans: randomized, double-blind, placebo-controlled fMRI. PLoS One. 2016;11(8):e0159930. doi:10.1371/journal.pone.0159930. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018244/
15. Naguib M, et al. Methylene blue in vasoplegic syndrome after cardiac surgery: randomized trial. Ann Thorac Surg. 2006;82(2):610-616. doi:10.1016/j.athoracsur.2006.02.057. https://pubmed.ncbi.nlm.nih.gov/16863753/
16. Shen J, Sun H, et al. Methylene blue for vasoplegic shock: meta-analysis. J Cardiothorac Vasc Anesth. 2020;34(12):3410-3417. doi:10.1053/j.jvca.2020.05.016. https://pubmed.ncbi.nlm.nih.gov/32592564/

BPC-157
17. Hackl MEE, Tomicic M, Malek-Zietek KE, et al. The stable gastric pentadecapeptide BPC-157: pleiotropic effects; limited clinical evidence. Pharmacol Res. 2024;185:106585. https://www.sciencedirect.com/science/article/pii/S1043661823003133
18. Staško A, et al. Intravenous BPC-157 in healthy adults: pilot safety. 2024. PubMed ID: 40131143. https://pubmed.ncbi.nlm.nih.gov/40131143/

Selank & Semax
19. Medvedev AE, et al. Selank vs medazepam in anxiety disorders: randomized study. Neurosci Behav Physiol. 2018;48(3):316-324. doi:10.1007/s11055-018-0581-6. https://link.springer.com/article/10.1007/s11055-018-0581-6

Regulatory 
20. FDA. Concerns about unapproved GLP-1 drugs used for weight loss (compounding & salt forms). 2023–2025. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
21. FDA. Certain bulk drug substances used in compounding may present significant safety risks (e.g., ipamorelin). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
22. USADA/WADA. BPC-157 status. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/